Viking Therapeutics (NASDAQ: VKTX) reported Q1 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19).

At March 31, 2022, Viking held cash, cash equivalents and short-term investments of $184.9 million, compared to $202.1 million as of December 31, 2021.

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.